Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

ByInvesting.com • Sep 28, 2023 Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer Merck ...

Keytruda plus Lenvima is an option for advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-based chemo in any setting ...

so far as it is the only regimen so far with long-term survival data (48 months-plus) in patients with a poorer prognosis. Approval of the Keytruda-Lenvima regimen would be a win-win for Merck ...

According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...

ByInvesting.com • 01 Jun 2023 Merck Reports KEYTRUDA Plus LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell ...

Cabozantinib plus nivolumab [Opdivo] and lenvatinib [Lenvima] plus pembrolizumab [Keytruda] are the [more recent] preferred regimens. 1 Then we have very specific types, like hereditary leiomyomatosis ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Keytruda might be prescribed by itself or with lenvatinib (Lenvima) in this case. TNBC with PD-L1 that’s recurring but can’t be removed by surgery, or is spreading from the breast to other ...